| Autor: |
Rogan AM, Hamilton TC, Young RC, Klecker RW Jr, Ozols RF |
| Jazyk: |
angličtina |
| Zdroj: |
Science (New York, N.Y.) [Science] 1984 Jun 01; Vol. 224 (4652), pp. 994-6. |
| DOI: |
10.1126/science.6372095 |
| Abstrakt: |
The effectiveness of adriamycin in the treatment of ovarian cancer and other human tumors has been limited by the development of drug resistance. Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly (150-fold) resistant cells. The potentiating effect of verapamil was due to inhibition of adriamycin efflux in the resistant cells. These results have led to a clinical trial of adriamycin and verapamil in refractory ovarian cancer patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
